{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:13:27Z","timestamp":1771632807935,"version":"3.50.1"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,21]]},"DOI":"10.1093\/ehjci\/jeac077","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:08:43Z","timestamp":1649934523000},"page":"1040-1041","source":"Crossref","is-referenced-by-count":1,"title":["Tafamidis and its stabilizing effects on transthyretin tetramers, the heart and eventually, scientific evidence"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-5158","authenticated-orcid":false,"given":"Ren\u00e9","family":"Rettl","sequence":"first","affiliation":[{"name":"Division of Cardiology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090 Vienna , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-5924","authenticated-orcid":false,"given":"Diana","family":"Bonderman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090 Vienna , Austria"},{"name":"Division of Cardiology and Emergency Medicine, Favoriten Clinic , Kundratstrasse 3, 1100 Vienna , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"2022072121193695100_jeac077-B1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2022072121193695100_jeac077-B2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"B\u00e9zard","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022072121193695100_jeac077-B3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ejhf.2080","article-title":"How to ATTR-ACT the perfect match?","volume":"23","author":"Bonderman","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022072121193695100_jeac077-B4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosiscript","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Hear J \u2013 Cardiovasc Imaging"},{"key":"2022072121193695100_jeac077-B5","doi-asserted-by":"crossref","first-page":"ehaa946.1029","DOI":"10.1093\/ehjci\/ehaa946.1029","article-title":"Effects of tafamidis on exercise capacity, cardiac function and myocardial amyloid deposition in patients with transthyretin amyloid cardiomyopathy","volume":"41","author":"Rettl","year":"2020","journal-title":"Eur Heart J"},{"key":"2022072121193695100_jeac077-B6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","article-title":"Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis","volume":"9","author":"Ternacle","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022072121193695100_jeac077-B7","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","author":"Rettl","year":"2021","journal-title":"Eur Hear J \u2013 Cardiovasc Imaging"},{"key":"2022072121193695100_jeac077-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9113446","article-title":"In vivo quantification of myocardial amyloid deposits in patients with suspected transthyretin-related amyloidosis (ATTR)","volume":"9","author":"Wollenweber","year":"2020","journal-title":"J Clin Med"},{"key":"2022072121193695100_jeac077-B9","article-title":"Quantification of myocardial amyloid deposition in tafamidis-treated patients with transthyretin amyloid cardiomyopathy","volume":"42","author":"Rettl","year":"2021","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/23\/8\/1040\/45046029\/jeac077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/23\/8\/1040\/45046029\/jeac077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T21:20:35Z","timestamp":1658438435000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article\/23\/8\/1040\/6576515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":9,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,2]]},"published-print":{"date-parts":[[2022,7,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjci\/jeac077","relation":{},"ISSN":["2047-2404","2047-2412"],"issn-type":[{"value":"2047-2404","type":"print"},{"value":"2047-2412","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,2]]}}}